Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US

Sponsor
Bristol-Myers Squibb
Study ID
NCT07557498
Status
Recruiting
Apply to this trial

Conditions

  • Obstructive Hypertrophic Cardiomyopathy (oHCM)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician experiences with mavacamten treatment, in the US community-based practice

Key Dates

Start date
Jan 15, 2026
Status verified
Apr 2026
Primary completion
Dec 14, 2026
Completion
Jun 17, 2027

Study Design

Enrollment
362 participants (estimated)

Arms

  • Arm: Group 1
    Participants with obstructive hypertrophic cardiomyopathy (oHCM) receiving mavacamten
  • Arm: Group 2
    Physicians treating patients diagnosed with obstructive hypertrophic cardiomyopathy (oHCM)

Primary Outcome Measure

Participant blood pressure (both systolic and diastolic) [ Time Frame: Baseline ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.